An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01

Trial Profile

An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Halofuginone (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Acronyms HALO
  • Sponsors Akashi Therapeutics; Halo Therapeutics
  • Most Recent Events

    • 06 Jul 2017 Status changed from suspended to discontinued as dosing stopped.
    • 03 Feb 2016 Status changed from active, no longer recruiting to suspended as dosing suspended temporarily, according to ClinicalTrials.gov record.
    • 25 Jan 2016 According to an Akashi Therapeutics media release, dosing and enrollment in this trial has been suspended based on discussions with the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top